Analysts Set Expectations for Zoetis’ Q4 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Stock analysts at William Blair decreased their Q4 2024 earnings per share (EPS) estimates for Zoetis in a note issued to investors on Monday, November 4th. William Blair analyst B. Vazquez now forecasts that the company will post earnings per share of $1.37 for the quarter, down from their previous forecast of $1.44. The consensus estimate for Zoetis’ current full-year earnings is $5.90 per share. William Blair also issued estimates for Zoetis’ Q2 2025 earnings at $1.67 EPS, Q3 2025 earnings at $1.70 EPS, FY2025 earnings at $6.36 EPS and Q3 2026 earnings at $1.91 EPS.

ZTS has been the topic of a number of other reports. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Wednesday, September 18th. BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $221.44.

Zoetis Price Performance

Shares of ZTS opened at $176.83 on Thursday. The firm has a market capitalization of $79.78 billion, a price-to-earnings ratio of 33.24, a price-to-earnings-growth ratio of 2.61 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69. Zoetis has a one year low of $144.80 and a one year high of $201.92. The stock’s fifty day moving average is $188.15 and its 200-day moving average is $179.35.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. The company had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The company’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $1.36 earnings per share.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a $0.432 dividend. This represents a $1.73 annualized dividend and a yield of 0.98%. The ex-dividend date is Thursday, October 31st. Zoetis’s dividend payout ratio is currently 32.52%.

Institutional Investors Weigh In On Zoetis

Several hedge funds have recently bought and sold shares of the business. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter worth about $31,000. First Personal Financial Services purchased a new stake in shares of Zoetis during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis during the 3rd quarter worth about $33,000. Quarry LP raised its stake in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares in the last quarter. Finally, LRI Investments LLC purchased a new stake in shares of Zoetis during the 1st quarter worth about $43,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.